Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in
steady-state conditions on the levodopa pharmacokinetics of a single dose of
immediate-release levodopa/carbidopa 100/25 mg and of a single dose of immediate-release
levodopa/benserazide 100/25 mg.